Interventions for smoking cessation and reduction in individuals with schizophrenia

Cochrane Database of Systematic Reviews

Volumn , Issue 3, 2008, Pages

  Tsoi, Daniel T ^a   Webster, Angela C ^b  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CARBON MONOXIDE; PLACEBO;

CLINICAL TRIAL; DEPRESSION; DISEASE SEVERITY; EXPIRED AIR; FOLLOW UP; HUMAN; MENTAL FUNCTION; META ANALYSIS; NEGATIVE SYNDROME; PATIENT COMPLIANCE; POSITIVE SYNDROME; REVIEW; SCHIZOPHRENIA; SELF REPORT; SMOKING; SMOKING CESSATION; SYSTEMATIC REVIEW; THERAPY EFFECT; TOBACCO DEPENDENCE;

EID: 55049107030     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD007253     Document Type: Review

References (18)

1. Addington 1997 Addington J, el Guebaly N, Addington D, Hodgins D. Readiness to stop smoking in schizophrenia. Canadian Journal of Psychiatry. Revue Canadienne de Psychiatrie 1997;42(1):49-52.
2. Adler 1993 Adler LE, Hoffer LD, Wiser A, Freedman R. Normalization of auditory physiology by cigarette smoking in schizophrenic patients. American Journal of Psychiatry 1993;150(12):1856-61.
3. Brown 2000 Brown S, Inskip H, Barraclough B. Causes of the excess mortality of schizophrenia. British Journal of Psychiatry 2000;177:212-7.
4. de Leon 2005 de Leon J, Diaz FJ. A meta-analysis of worldwide studies demonstrates an association between schizophrenia and tobacco smoking behaviors. Schizophrenia Research 2005;76(2/3):135-57.
5. Dixon 1999 Dixon L. Dual diagnosis of substance abuse in schizophrenia: prevalence and impact on outcomes. Schizophrenia Research 1999;35 Suppl:S93-S100.
6. DSMIV 1994 American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorder. 4. Washington, DC: American Psychiatric Association, 1994.
7. George 2000 George TP, Ziedonis DM, Feingold A, Pepper WT, Satterburg CA, Winkel J, et al.Nicotine transdermal patch and atypical antipsychotic medications for smoking cessation in schizophrenia. American Journal of Psychiatry 2000;157(11):1835-42.
8. Higgins 2003 Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;7414:557-60.
9. Higgins 2008 Higgins JPT, Green S [eds]. Cochrane Handbook for Systematic Reviews of Interventions,5.0.0 [updated February 2008]. The Cochrane Collaboration, 2008.
10. ICD10 2003 World Health Organization. International Classification of Diseases. WHO, 2003.
11. Kelly 1999 Kelly C, McCreadie RG. Smoking habits, current symptoms, and premorbid characteristics of schizophrenic patients in Nithsdale, Scotland. American Journal of Psychiatry 1999;156(11):1751-7.
12. Lichtermann 2001 Lichtermann D, Ekelund J, Pukkala E, Tanskanen A, Lonnqvist J. Incidence of cancer among persons with schizophrenia and their relatives. Archives of General Psychiatry 2001;58(6):573-8.
13. Olincy 1997 Olincy A, Young DA, Freedman R. Increased levels of the nicotine metabolite cotinine in schizophrenic smokers compared to other smokers. Biological Psychiatry 1997;42(1):1-5.
14. Sacco 2004 Sacco KA, Bannon KL, George TP. Nicotinic receptor mechanisms and cognition in normal states and neuropsychiatric disorders. Journal of Psychopharmacology 2004;18(4):457-74.
15. USDHHS 2000 United States Department of Health and Human Services. Treating tobacco use and dependence. Rockville, MD: Agency for Healthcare Research Quality, 2000.
16. West 2005 West R, Hajek P, Stead L, Stapleton J. Outcome criteria in smoking cessation trials: proposal for a common standard. Addiction 2005;100(3):299-303.
17. WHO 2003 World Health Organization. Policy recommendations on smoking cessation and treatment of tobacco dependence. WHO, France, 2003.
18. Williams 2005 Williams JM, Ziedonis DM, Abanyie F, Steinberg ML, Foulds J, Benowitz NL. Increased nicotine and cotinine levels in smokers with schizophrenia and schizoaffective disorder is not a metabolic effect. Schizophrenia Research 2005;79(2-3):323-35.